Stephen Berenson - 03 May 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
03 May 2024
Net transactions value
$0
Form type
4
Filing time
07 May 2024, 17:10:08 UTC
Previous filing
08 Apr 2024
Next filing
03 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +732 +3.4% 22,203 03 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -732 -100% $0.000000* 0 03 May 2024 Common Stock 732 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Award $0 +7,557 $0.000000 7,557 06 May 2024 Common Stock 7,557 $122.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The shares subject to this restricted stock unit award vested in full on May 3, 2024.
F3 This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.